We hypothesize that the protective effect of hypertension, diabetes, and CAD in AKI patients may be due to the widespread use of renoprotective medications in this group, including ACE inhibitors, ARBs, and SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is Hypertension.